Ko-Chung Yen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ko-Chung Yen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Feng-Huei Lin
4 shared publicationsJian-Yuan Huang
Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, Taipei 10617, Taiwan
3 shared publicationsKai-Chiang Yang
3 shared publicationsChing-Li Tseng
2 shared publicationsChang-Chin Wu
1 shared publicationChao-Tsang Lu
Institute of Life Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan, Republic of China
1 shared publication
Latest Publications
- 8 December 2015
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 4 (2) , 237-244
Fabrication of keratin/fibroin membranes by electrospinning for vascular tissue engineering
Cardiovascular diseases (CVDs) are some of the leading causes of death and bypass surgery is one of the common treatment options for the critical CVD patients.
- 8 December 2015
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 4 (2) , 237-244
Fabrication of keratin/fibroin membranes by electrospinning for vascular tissue engineering
Cardiovascular diseases (CVDs) are some of the leading causes of death and bypass surgery is one of the common treatment options for the critical CVD patients.
- 1 December 2012
- Published by Elsevier in Process Biochemistry
- Vol. 47 (12) , 1919-1925
Cholaminchloride hydrochloride-cationized gelatin/calcium-phosphate nanoparticles as gene carriers for transgenic chicken production
- 1 December 2012
- Published by Elsevier in Process Biochemistry
- Vol. 47 (12) , 1919-1925
Cholaminchloride hydrochloride-cationized gelatin/calcium-phosphate nanoparticles as gene carriers for transgenic chicken production
- 1 December 2011
- Published by Bentham Science Publishers Ltd. in Current Nanoscience
- Vol. 7 (6) , 932-937
Preparation and Characterization of Cisplatin-Incorporated Gelatin Nanocomplex for Cancer Treatment
To develop a polymer – anticancer drug conjugate accompanied by a reduction of anticipated side effects and therapeutic improvement, we employed gelatin nanoparticles (GPs) as carriers for cisplatin (CDDP). The GPs-cisplatin nanocomplex (GP-Pt) was fabricated by a two-step desolvation process from gelatin type A. The parameters for the optimal GP-Pt preparation were investigated, including temperature, the pH of the gelatin solution, glutaraldehyde (GA) concentration, and the time point for CDDP addition. GP-Pt was characterized by its size, surface charge, morphology, and drug release rate. The chemical and physical properties of GP-Pt have been studied using X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR), differential thermal analysis (DTA), and thermal gravimetric analysis (TGA). In vivo anticancer effects and reductions in toxicity were evaluated by intratumorally injecting GP-Pt into SCID mice that had been injected with human lung carcinoma cells (A549 cells) as a subcutaneous cancer model. The GP-Pt prepared with gelatin type A solution at pH 2.5 with a 0.4 % GA addition achieved the smallest size. The FT-IR assay result showed that GPs conjugated with cisplatin via an ion-exchange of the carboxyl group of the gelatin. In vivo anticancer effects were revealed in that GP-Pt could effectively decrease the tumor size, and mice treated with GP-Pt lived longer than those treated with free CDDP, which indicates reduced toxicity due to cisplatin. The systematic investigation of the synthesis parameters showed that it is possible to prepare GPs with a small size distribution and with the incorporation of high cisplatin. We showed that the GP-Pt nanocomplex was less toxic than the free drug, and that it could effectively reduce the tumor size and toxic effects in mice grafted with A549 cells. The results of this study suggest that GP-Pt could be slowly released to reduce the toxicity of cisplatin, and that it may be used as a potential drug delivery system for chemotherapy.
- 1 December 2011
- Published by Bentham Science Publishers Ltd. in Current Nanoscience
- Vol. 7 (6) , 932-937
Preparation and Characterization of Cisplatin-Incorporated Gelatin Nanocomplex for Cancer Treatment
To develop a polymer – anticancer drug conjugate accompanied by a reduction of anticipated side effects and therapeutic improvement, we employed gelatin nanoparticles (GPs) as carriers for cisplatin (CDDP). The GPs-cisplatin nanocomplex (GP-Pt) was fabricated by a two-step desolvation process from gelatin type A. The parameters for the optimal GP-Pt preparation were investigated, including temperature, the pH of the gelatin solution, glutaraldehyde (GA) concentration, and the time point for CDDP addition. GP-Pt was characterized by its size, surface charge, morphology, and drug release rate. The chemical and physical properties of GP-Pt have been studied using X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR), differential thermal analysis (DTA), and thermal gravimetric analysis (TGA). In vivo anticancer effects and reductions in toxicity were evaluated by intratumorally injecting GP-Pt into SCID mice that had been injected with human lung carcinoma cells (A549 cells) as a subcutaneous cancer model. The GP-Pt prepared with gelatin type A solution at pH 2.5 with a 0.4 % GA addition achieved the smallest size. The FT-IR assay result showed that GPs conjugated with cisplatin via an ion-exchange of the carboxyl group of the gelatin. In vivo anticancer effects were revealed in that GP-Pt could effectively decrease the tumor size, and mice treated with GP-Pt lived longer than those treated with free CDDP, which indicates reduced toxicity due to cisplatin. The systematic investigation of the synthesis parameters showed that it is possible to prepare GPs with a small size distribution and with the incorporation of high cisplatin. We showed that the GP-Pt nanocomplex was less toxic than the free drug, and that it could effectively reduce the tumor size and toxic effects in mice grafted with A549 cells. The results of this study suggest that GP-Pt could be slowly released to reduce the toxicity of cisplatin, and that it may be used as a potential drug delivery system for chemotherapy.
- 1 January 2011
- Published by Elsevier in Biomedicine & Aging Pathology
- Vol. 1 (1) , 46-51
Sintered dicalcium pyrophosphate decreases bone turnover rate in osteoporotic rat: A study on serum biochemical bone turnover markers
- 1 January 2011
- Published by Elsevier in Biomedicine & Aging Pathology
- Vol. 1 (1) , 46-51
Sintered dicalcium pyrophosphate decreases bone turnover rate in osteoporotic rat: A study on serum biochemical bone turnover markers
- 1 July 2009
- Published by Elsevier in Biomaterials
- Vol. 30 (20) , 3476-3485
The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation
- 1 July 2009
- Published by Elsevier in Biomaterials
- Vol. 30 (20) , 3476-3485
The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation
- 1 March 2008
- Published by SAGE Publications in Textile Research Journal
- Vol. 78 (3) , 254-257
Preparation of Polyethylene Oxide/Chitosan Fiber Membranes by Electrospinning and the Evaluation of Biocompatibility
Chitosan is an excellent material for medical use because it is nontoxic, has good biocompatibility, exhibits antimicrobial activity, supports the healing of wounds, etc. Electrospinning yields nanofibers which have wide applications, such as high-performance filters, biomaterial scaffolds for vascular grafts or wound dressings, etc. In this investigation, electrospinning was performed in an electric field of 0.6 kV/cm with a polyethylene oxide to chitosan ratio of 60:40. The polymer nanofibers had diameters that ranged from a few nanometers to several micrometers (approximately 30 nm).
- 1 March 2008
- Published by SAGE Publications in Textile Research Journal
- Vol. 78 (3) , 254-257
Preparation of Polyethylene Oxide/Chitosan Fiber Membranes by Electrospinning and the Evaluation of Biocompatibility
Chitosan is an excellent material for medical use because it is nontoxic, has good biocompatibility, exhibits antimicrobial activity, supports the healing of wounds, etc. Electrospinning yields nanofibers which have wide applications, such as high-performance filters, biomaterial scaffolds for vascular grafts or wound dressings, etc. In this investigation, electrospinning was performed in an electric field of 0.6 kV/cm with a polyethylene oxide to chitosan ratio of 60:40. The polymer nanofibers had diameters that ranged from a few nanometers to several micrometers (approximately 30 nm).